Literature DB >> 1716654

A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids.

B Rombaut1, K Andries, A Boeyé.   

Abstract

The thermal denaturation of poliovirus virions and procapsids in the 42 to 48 degrees C range was studied using N- and H-specific monoclonal antibodies. The half-life of the N antigen of Mahoney and Sabin 1 virions was extended 50- to 250-fold by either 10 microM WIN 51711 or R 78206. The minimum concentrations required for full stabilization at 46 degrees C (1.0 microM for WIN 51711, 0.2 microM for R 78206) were independent of the strain or serotype of the virus; 30 to 60 molecules of stabilizer per virion were required for full protection. R 78206 was the most efficient stabilizer of Mahoney procapsids; the half-life of the N-specific epitopes of these particles at 44 degrees C was extended from less than 1 min to 1 day.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716654     DOI: 10.1099/0022-1317-72-9-2153

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.

Authors:  A W Dove; V R Racaniello
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Molecular dynamics investigation of the effect of an antiviral compound on human rhinovirus.

Authors:  D K Phelps; C B Post
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

3.  Molecular dynamics simulations of human rhinovirus and an antiviral compound.

Authors:  B Speelman; B R Brooks; C B Post
Journal:  Biophys J       Date:  2001-01       Impact factor: 4.033

4.  Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus.

Authors:  S Curry; E Fry; W Blakemore; R Abu-Ghazaleh; T Jackson; A King; S Lea; J Newman; D Stuart
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Effect of a capsid-stabilizing pyridazinamine, R 78206, on the eclipse and intracellular location of poliovirus.

Authors:  O Ofori-Anyinam; R Vrijsen; P Kronenberger; A Boeyé
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present.

Authors:  A G Mosser; R R Rueckert
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound.

Authors:  K Andries; B Rombaut; B Dewindt; A Boeyé
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.

Authors:  A G Mosser; J Y Sgro; R R Rueckert
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Foot-and-mouth disease virus assembly: processing of recombinant capsid precursor by exogenous protease induces self-assembly of pentamers in vitro in a myristoylation-dependent manner.

Authors:  Stewart Goodwin; Tobias J Tuthill; Armando Arias; Richard A Killington; David J Rowlands
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

10.  Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation.

Authors:  B Rombaut; B Verheyden; K Andries; A Boeyé
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.